557Standing interim approval to prescribe buprenorphine

557 Standing interim approval to prescribe buprenorphine and methadone for patients of certain institutions designated prescriber includes an intern doctor only if the intern doctor is acting under the direct supervision of a doctor. (2) A designated prescriber is approved (the interim approval) to prescribe buprenorphine or methadone if— (a) the designated prescriber— (i) is working at a hospital and prescribes the medicine for an outpatient at the hospital; or (ii) is working at any of the following institutions and prescribes the medicine for a patient of the institution: (A) a correctional centre; (B) a CYP detention place; (C) an opioid dependency treatment centre operated by the Territory; or Note Institution includes a correctional centre and a CYP detention place (see s 652). (iii) prescribes the medicine for a person in police custody; and (b) the buprenorphine or methadone is prescribed in accordance with the opioid dependency treatment guidelines; and Note Opioid dependency treatment guidelines—see the dictionary. (c) the designated prescriber makes an application under section 560 to prescribe the medicine not later than 72 hours after the designated prescriber first prescribes buprenorphine or methadone for the patient.

use (3) The interim approval ends— (a) if the chief health officer approves the application under division 13.1.3—when the designated prescriber is given notice of the approval; or (b) if the application under section 560 is withdrawn—on the withdrawal of the application; or (c) if the chief health officer refuses to approve the application and the 7-day period mentioned in section 565 (2) (Applications for review of unfavourable CHO decisions for approvals) ends without an application for review being made—at the end of the 7-day period; or (d) if the chief health officer refers the application to the medicines advisory committee or an application is made to the committee under section 565—when the designated prescriber is given notice of the chief health officer’s decision under section 573 (Medicines advisory committee—recommendations to CHO). Division 13.1.3 Chief health officer controlled medicines approvals